ZLAB Zai Lab Ltd

  1. Stocks
  2. Healthcare
  3. NASDAQ: ZLAB

Price (delayed)

$17.375

Market cap

$1.95B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.7

Enterprise value

$1.43B

?
Relative Growth: Rel. Growth: 49
Relative Strength: Rel. Strength: 16
Relative Valuation: Rel. Valuation: 14
Relative Profitability: Rel. Profitability: 30

Zai Lab ) is an innovative commercial stage biopharmaceutical company focused on bringing transformative medicines for cancer, infectious and autoimmune diseases to patients in China and around the world. To ...

Highlights
The company's net income rose by 29% YoY
Zai Lab's revenue has increased by 8% YoY
The EPS has grown by 29% YoY but it has contracted by 6% from the previous quarter
The quick ratio is down by 29% year-on-year and by 3.7% since the previous quarter
The debt has grown by 21% YoY and by 3.4% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://www.zailaboratory.com
Peers: OPK ORGO

Key stats

What are the main financial stats of ZLAB

ZLAB stock price

How has the Zai Lab stock price performed over time
Intraday
1.19%
1 week
-5.98%
1 month
-18.12%
1 year
-51.84%
YTD
-1.5%
QTD
-7.63%

Financial performance

How have Zai Lab's revenue and profit performed over time
Revenue
$453.28M
Gross profit
$262.51M
Operating income
-$238.61M
Net income
-$178.12M
Gross margin
57.9%
Net margin
-39.3%
The net margin has grown by 35% YoY but it has contracted by 3.1% from the previous quarter
The company's net income rose by 29% YoY
The company's operating margin rose by 19% YoY but it fell by 7% QoQ
Zai Lab's operating income has increased by 12% YoY but it has decreased by 6% QoQ

Price vs fundamentals

How does ZLAB's price correlate with its fundamentals

Growth

What is Zai Lab's growth rate over time

Valuation

What is Zai Lab stock price valuation
P/E
N/A
P/B
2.9
P/S
4.24
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
3.16
The EPS has grown by 29% YoY but it has contracted by 6% from the previous quarter
The stock's P/B is 26% below its last 4 quarters average of 3.9 and 24% below its 5-year quarterly average of 3.8
The equity has contracted by 18% YoY and by 7% from the previous quarter
ZLAB's price to sales (P/S) is 83% lower than its 5-year quarterly average of 24.6 and 36% lower than its last 4 quarters average of 6.5
Zai Lab's revenue has increased by 8% YoY

Efficiency

How efficient is Zai Lab business performance
The ROS has grown by 35% YoY
The ROA has grown by 33% YoY but it has contracted by 3.3% from the previous quarter
ZLAB's ROE is up by 27% YoY but it is down by 7% QoQ
Zai Lab's return on invested capital has increased by 9% YoY but it has decreased by 5% QoQ

Dividends

What is ZLAB's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for ZLAB.

Financial health

How did Zai Lab financials performed over time
The total assets is 153% more than the total liabilities
The quick ratio is down by 29% year-on-year and by 3.7% since the previous quarter
The current ratio has contracted by 26% YoY and by 2% from the previous quarter
The debt is 65% less than the equity
Zai Lab's debt to equity has increased by 46% YoY and by 13% from the previous quarter
The debt has grown by 21% YoY and by 3.4% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.